Stifel lowered the firm’s price target on Vor Bio (VOR) to $40 from $55 and keeps a Buy rating on the shares. The global Phase 3 UPSTREAM MG trial evaluating telitacicept in generalized Myasthenia Gravis continues to enroll patients across multiple regions and topline data is still anticipated in the first half of 2027, notes the analyst, whose reduced price target primarily reflects revised financing assumptions stemming from greater than $330M of equity capital raised in less than five months.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Bio price target lowered to $40 from $55 at Stifel
- Vor Biopharma: Solid Clinical Execution and Strengthened Balance Sheet Support Buy Rating and Long-Term Growth Outlook
- Vor Bio doses first patient in UPSTREAM SjD study
- Vor Bio initiated with a Buy at Jefferies
- Vor Biopharma: Strategic Autoimmune Pivot and Telitacicept’s >$2B gMG/SjD Opportunity Underpins Buy Rating